Drug
Tobramycin Inhalation
Tobramycin Inhalation: highest development phase Post-Market, developed by Chiesi Farmaceutici, Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Chiesi Farmaceutici, Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| tobramycin inhalation NCT02440828 | Post-Market | Ventilator Associated Pneumonia (VAP) |
| Tobramycin inhalation powder NCT01069705 | Phase 3 | Pulmonary Infections |
Latest
No recent events.
Follow Tobramycin Inhalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.